PLYMOUTH MEETING, Pa.,
Nov. 9, 2021 /PRNewswire/
-- INOVIO (NASDAQ:INO), a biotechnology company focused on
rapidly bringing to market precisely designed DNA medicines to help
protect people from infectious diseases and treat people with
cancer, and HPV-associated diseases, today reported financial
results for the quarter ended September 30,
2021. INOVIO's management will host a live conference call
and webcast at 4:30 p.m. Eastern Time
today to discuss financial results and provide a general business
update. The live webcast and replay may be accessed by visiting
INOVIO's website at
http://ir.inovio.com/events-and-presentations/default.aspx.
Dr. J. Joseph Kim, President and
CEO of INOVIO, said, "This morning, INOVIO announced that the U.S.
Food and Drug Administration (FDA) provided authorization to
proceed for INOVIO's INNOVATE Phase 3 segment for its COVID-19
vaccine candidate, INO-4800, in the U.S. We're pleased to have the
opportunity for U.S. clinical trial participants to potentially
contribute to the enrollment in our INNOVATE Phase 3 segment.
Today's U.S. announcement builds on our intensive global efforts in
India, Brazil, Philippines, Mexico, Colombia, and Thailand where we have received authorizations
to date.
"With much of the world still requiring broader access to
vaccines, INO-4800 is particularly well-positioned to address
global vaccine needs, having been shown, in clinical trials
to-date, to be well-tolerated and to generate balanced immune
responses which comprise both T and B cell engagement. In addition,
INO-4800 has demonstrated a favorable thermostability profile that
could facilitate global distribution. I am pleased to share that
the dosing for INNOVATE Phase 3 segment is underway and we aim
to have interim efficacy data in the first half 2022."
INOVIO Key Updates & Third Quarter 2021
Highlights
Key Updates
- INOVIO announced that the U.S. FDA provided authorization to
proceed for INOVIO's INNOVATE Phase 3 segment for INO-4800 in the
U.S. INOVIO now has the opportunity for U.S. clinical trial
participants to potentially contribute to the enrollment in the
INNOVATE Phase 3 segment. Since August
2021, INOVIO has received authorization to conduct its
INNOVATE Phase 3 global efficacy segment in: Brazil, Colombia, Mexico, the
Philippines, India, the
U.S. and, most recently, Thailand.
Dosing is underway and the company aims to have interim efficacy
data in the first half 2022.
- The WHO shared on October 26,
2021 that INO-4800 is one of two vaccine candidates
initially selected for its randomized, global Phase 3 clinical
trial, Solidarity Trial Vaccines. More information can be found on
the WHO's website.
- Subsequent to the quarter end, INOVIO's Phase 1 clinical data
on homologous boosting of INO-4800 was posted as a pre-print in
MedRxiv. The paper, titled "SARS-CoV-2 DNA Vaccine INO-4800
Induces Durable Immune Responses Capable of Being Boosted in a
Phase 1 Open-Label Trial," found that among the full Phase 1 cohort
of 120 participants –99 (82.5%) participants, received an optional
booster (or third) dose – INO-4800 produced broad-based immune
responses and was well-tolerated as both a two-dose series and as a
homologous booster dose in adults of all ages.
- INOVIO's partner Advaccine received regulatory approval to
conduct two clinical trials in China investigating boosting with INO-4800.
The studies will include prime-boost sequential immunizations using
INO-4800 and an inactivated COVID-19 vaccine.
- Subsequent to the quarter end, INOVIO completed enrollment
(n=220) of its Phase 1B clinical
trial for INO-4500, its DNA vaccine candidate for Lassa fever. This
trial (LSV-002) is the first vaccine clinical trial for Lassa fever
conducted in West Africa, where
the viral illness is endemic. INOVIO is advancing INO-4500 with
full funding from the Coalition for Epidemic Preparedness
Innovations (CEPI).
- INOVIO, with Regeneron, continues to evaluate findings from the
Phase 1/2 novel combination trial of DNA medicines INO-5401 and
INO-9012 in combination with PD-1 inhibitor cemiplimab – which is
being jointly developed by Regeneron and Sanofi – for the treatment
of newly diagnosed Glioblastoma Multiforme (GBM).
INOVIO Third Quarter 2021 and Subsequent Program
Updates
DNA Vaccine Candidates
INO-4800: COVID-19 Vaccine Candidate in Solidarity Trial
Vaccines
INOVIO's INO-4800 is one of two initial vaccine candidates
included in the WHO's Solidarity Trial Vaccines, which is designed
to "rapidly evaluate the efficacy and safety of promising new
candidate vaccines selected by an independent vaccine
prioritization advisory group composed of leading scientists and
experts." Recruitment for the trial has begun in Colombia, Mali and the
Philippines; enrollment is expected at more than 40 sites
across the three countries. According to the WHO, the trial "has
the additional potential to uncover second-generation vaccines with
greater efficacy, conferring greater protection against variants of
concern, offering longer duration of protection, and/or using
needle-free routes of administration."
INO-4800 in INNOVATE Phase 3 Trial
With the FDA's authorization to proceed for INOVIO's INNOVATE
Phase 3 segment for INO-4800 in the U.S., INOVIO now has the
opportunity for U.S. clinical trial participants to potentially
contribute to the enrollment in this global Phase 3 trial. The FDA
has lifted the partial clinical hold following the FDA's review of
additional non-clinical, clinical, and device information provided
by INOVIO. U.S. announcement builds on our intensive global efforts
in India, Brazil, Philippines, Mexico, Colombia, and Thailand where we have received authorizations
to date.
Dosing is underway and the company aims to have interim Phase 3
efficacy data from INNOVATE in the first half of 2022. Pending
favorable clinical efficacy data, the company plans to apply for
emergency use authorization in the respective countries, where such
mechanism is available.
In addition to receiving regulatory approval to proceed with
INNOVATE Phase 3 in Colombia,
INOVIO also signed a non-binding MOU with Colombia's Ministry of Health and Social
Protection, reflecting the intent to advance efforts to combat the
continued threat posed by COVID-19 and to better prepare for future
public health emergencies within Colombia. The agreement creates a framework
for a collaborative arrangement under which INOVIO and Colombia's government plan to explore
knowledge sharing, technology licensing, and capacity building
towards developing and producing vaccines along with
biopharmaceuticals in Colombia.
The potential results of these efforts include developing local
manufacturing capabilities for INOVIO's DNA medicines and related
products and technologies.
Boosting
INOVIO continues to study the boosting capabilities of INO-4800
following an initial primary vaccination series using a different
COVID-19 vaccine series (heterologous) or with INO-4800
(homologous). During the third quarter, INOVIO's partner Advaccine
received regulatory authorization to conduct two clinical trials in
China investigating boosting with
INO-4800. The studies will include prime-boost sequential
immunizations using INO-4800 and an inactivated COVID-19
vaccine.
INOVIO's Phase 1 clinical data on homologous boosting of
INO-4800 was posted in pre-print form at MedRxiv.org after
quarter end. The paper, titled "SARS-CoV-2 DNA Vaccine INO-4800
Induces Durable Immune Responses Capable of Being Boosted in a
Phase 1 Open-Label Trial," reports that among the full Phase 1
cohort of 120 participants – of which 82.5%, or 99 participants,
received an optional booster (or third) dose – INO-4800 produced
balanced immune responses and was well-tolerated as both a two-dose
series and as a homologous booster dose in adults of all ages.
Notably, a durable anti-SARS-CoV-2 antibody response was
observed six months following the second dose, and a homologous
booster dose administered between six-to-10.5 months following the
second dose also significantly increased humoral and T cell
responses. Furthermore, INO-4800 was reported to be well-tolerated,
with no treatment-related serious adverse events. Most adverse
events were mild in severity and did not increase in frequency with
age and subsequent dosing. The newly reported results are
consistent with previously shared data from the Phase 2 segment of
INOVIO's INNOVATE Phase 2/3
trial.
INO-4500: Lassa Fever
Subsequent to the quarter end, the company announced full
enrollment in its Phase 1B clinical
trial for INO-4500, its DNA vaccine candidate for Lassa fever. This
trial (LSV-002) is ongoing at the Noguchi Memorial Institute for
Medical Research in Accra, Ghana,
and is the first vaccine clinical trial for Lassa fever conducted
on the African continent. The viral illness is endemic in
West Africa. The Phase
1B clinical trial enrolled 220 adult
participants who are 18-50 years old, with the primary endpoints of
evaluating safety and immunogenicity in an African population. The
dosing regimen involves two vaccinations at Days 0 and 28 with
either 1.0 mg or 2.0 mg dosing levels. In addition to providing
insights on INO-4500's safety and immunogenicity profile, the trial
will inform dose selection for subsequent Phase 2 testing in
West Africa. INOVIO is advancing
INO-4500 with funding from CEPI, with INOVIO and CEPI planning to
establish a stockpile for emergency use after a Phase 2 trial, if
successful.
HPV-associated Diseases
VGX-3100: Cervical, Vulvar, and Anal HSIL
REVEAL 1 / REVEAL 2 (Cervical HSIL)
INOVIO has completed follow-up of subjects in REVEAL 1
(Randomized Evaluation of VGX-3100 and
Electroporation for the treatment of Cervical HSIL),
a Phase 3 pivotal trial evaluating VGX-3100 for the treatment of
cervical high-grade squamous intraepithelial lesions caused by
HPV-16 and/or HPV-18, for safety and durability of virological
clearance for 18 months following the last administration. The
company expects to present its findings later this year.
Additionally, INOVIO is advancing its partnership with QIAGEN to
co-develop an in-vitro diagnostic tool based on a bio-marker
to guide clinical decision-making for the use of VGX-3100 in
cervical HSIL.
REVEAL 2 is on track to complete enrollment of 198 adult women
with histologically confirmed cervical HSIL before year end.
Participants will be evaluated for evidence of cervical HSIL on
histology as well as evidence of HPV-16 or HPV-18 in cervical
samples by type-specific HPV testing at the Week 36 visit
accompanied with a one-month safety follow-up.
Immuno-oncology
INO-5401: Newly Diagnosed Glioblastoma Multiforme
(GBM)
INOVIO, along with our collaborator Regeneron, continues to
evaluate findings from the Phase 1/2 novel combination trial of DNA
medicines INO-5401 (DNA plasmid encoding for HTERT, WT1, and PSMA
cancer antigens) and INO-9012 (DNA plasmid encoding IL-12), two of
INOVIO's immunotherapeutic agents, in combination with PD-1
inhibitor cemiplimab – which is being jointly developed by
Regeneron and Sanofi – for the treatment of newly diagnosed GBM.
Two-year (24 months) overall survival data, including correlative
immunology and tissue data, will be presented at a pre-conference
workshop of the Society of Immunotherapy of Cancer's (SITC)
36th Annual Meeting this month.
Third Quarter 2021 Financial Results
Total revenue was $292,000 for the
three months ended September 30,
2021, compared to $236,000 for
the same period in 2020. Total operating expenses were $60.2 million compared to $36.6 million for the same period in 2020.
INOVIO's net loss for the quarter ended September 30, 2021
was $60.2 million, or $0.29 per basic and diluted share, compared to
net income of $19.2 million, or
$0.12 per basic and $0.11 diluted share, for the quarter ended
September 30, 2020.
The net income for the 2020 quarter was primarily due to the
$35.3 million change in fair value of
the derivative liability related to the embedded conversion feature
in our August 2019 Convertible Bonds,
which was revalued at each reporting period and then immediately
prior to the full conversion of these bonds into shares of the
Company's common stock in August
2020. The Company also recorded a gain on investment in
affiliated entities of $27.0 million
during the quarter, primarily related to the sale of its equity
interest in GeneOne. Without the non-cash gain on derivative
liability and the gain on investment in affiliated entities, the
Company's net loss for the quarter would have been $43.1 million and basic net loss per share would
have been $0.26.
Operating Expenses
Research and development (R&D) expenses for the three months
ended September 30, 2021, were
$47.1 million compared to
$26.5 million for the same period in
2020. The increase in R&D expenses was primarily related to
higher drug manufacturing, outside services and clinical study
expenses related to INO-4800, an increase in drug manufacturing and
clinical study expenses related to INO-4802 and higher employee and
contractor compensation. The increase was also due to a decrease in
contra-research and development expense recorded from grant
agreements of $2.4 million, among
other variances
General and administrative (G&A) expenses were $13.2 million for the three months ended
September 30, 2021, versus
$10.1 million for the same period in
2020. The increase in G&A expenses was primarily related to an
increase in employee compensation, including non-cash stock-based
compensation, partially offset by lower expenses for work performed
related to corporate marketing and communications, among other
variances.
Capital Resources
As of September 30, 2021, cash and cash equivalents and
short-term investments were $394.9
million compared to $411.6
million as of December 31, 2020. As of
September 30, 2021, the Company had 210.4 million common
shares outstanding and 227.0 million common shares outstanding on a
fully diluted basis, after giving effect to the exercise, vesting
and conversion, as applicable, of its outstanding options,
restricted stock units, convertible preferred stock, and
convertible debt.
INOVIO's balance sheet and statement of operations are provided
below. Additional information is included in INOVIO's quarterly
report on Form 10-Q for the quarter ended September 30, 2021,
which can be accessed at:
http://ir.inovio.com/financials/default.aspx.
Conference Call / Webcast Information
INOVIO's management will host a live conference call and webcast
at 4:30 p.m. Eastern Time today to
discuss INOVIO's financial results and provide a general business
update.
The live webcast and a replay may be accessed by visiting
INOVIO's website at
http://ir.inovio.com/events-and-presentations/default.aspx.
About INOVIO
INOVIO is a biotechnology company focused on rapidly bringing to
market precisely designed DNA medicines to treat and protect people
from infectious diseases, cancer, and diseases associated with HPV.
INOVIO is the first company to have clinically demonstrated that a
DNA medicine can be delivered directly into cells in the body via a
proprietary smart device to produce a robust and tolerable immune
response. Specifically, INOVIO's lead therapeutic candidate
VGX-3100 met primary and secondary endpoints for all evaluable
subjects in REVEAL 1, the first of two, Phase 3 trials for
precancerous cervical dysplasia, demonstrating ability to destroy
and clear both high-grade cervical lesions and the underlying
high-risk HPV-16/18. INOVIO is also evaluating INO-4800, a DNA
vaccine candidate against COVID-19, in a Phase 2/3 clinical trial;
the Phase 3 segment of which has received regulatory approvals to
proceed in Colombia, Mexico, Brazil, Philippines, India, Thailand, and the
United States. INOVIO's partners, Advaccine
Biopharmaceuticals and International Vaccine Institute, are also
evaluating INO-4800 in ongoing clinical trials in China and South
Korea, respectively.
Partners and collaborators include Advaccine, ApolloBio
Corporation, AstraZeneca, The Bill & Melinda Gates Foundation,
Coalition for Epidemic Preparedness Innovations, Defense Advanced
Research Projects Agency/Joint Program Executive Office for
Chemical, Biological, Radiological and Nuclear Defense/Department
of Defense, HIV Vaccines Trial Network, International Vaccine
Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium,
National Cancer Institute, National Institutes of Health, National
Institute of Allergy and Infectious Diseases, Ology Bioservices,
the Parker Institute for Cancer Immunotherapy, Plumbline Life
Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher
Scientific, University of Pennsylvania,
Walter Reed Army Institute of Research, and The Wistar Institute.
For more information, visit www.inovio.com.
CONTACTS:
Media: Jeff Richardson,
267-440-4211, jrichardson@inovio.com
Investors: Ben Matone, 484-362-0076,
ben.matone@inovio.com
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
DNA medicines, our expectations regarding our research and
development programs, including the planned initiation and conduct
of preclinical studies and clinical trials and the availability and
timing of data from those studies and trials, and our ability to
successfully manufacture and produce large quantities of our
product candidates if they receive regulatory approval. Actual
events or results may differ from the expectations set forth herein
as a result of a number of factors, including uncertainties
inherent in pre-clinical studies, clinical trials, product
development programs and commercialization activities and outcomes,
our ability to secure sufficient manufacturing capacity to mass
produce our product candidates, the availability of funding to
support continuing research and studies in an effort to prove
safety and efficacy of electroporation technology as a delivery
mechanism or develop viable DNA medicines, our ability to support
our pipeline of DNA medicine products, the ability of our
collaborators to attain development and commercial milestones for
products we license and product sales that will enable us to
receive future payments and royalties, the adequacy of our capital
resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
us or our collaborators, including alternatives that may be more
efficacious or cost effective than any therapy or treatment that we
and our collaborators hope to develop, issues involving product
liability, issues involving patents and whether they or licenses to
them will provide us with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
we can finance or devote other significant resources that may be
necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of our technology by potential
corporate or other partners or collaborators, capital market
conditions, the impact of government healthcare proposals and other
factors set forth in our Annual Report on Form 10-K for the year
ended December 31, 2020, our
Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and other filings we make from
time to time with the Securities and Exchange Commission. There can
be no assurance that any product candidate in our pipeline will be
successfully developed, manufactured or commercialized, that final
results of clinical trials will be supportive of regulatory
approvals required to market products, or that any of the
forward-looking information provided herein will be proven
accurate. Forward-looking statements speak only as of the date of
this release, and we undertake no obligation to update or revise
these statements, except as may be required by law.
INOVIO
Pharmaceuticals, Inc. CONDENSED CONSOLIDATED BALANCE
SHEETS
|
|
|
September
30,
2021
|
|
December
31,
2020
|
|
|
|
ASSETS
|
|
|
Current
assets:
|
|
|
Cash and cash
equivalents
|
$
|
67,941,337
|
|
|
$
|
250,728,118
|
|
Short-term
investments
|
326,999,236
|
|
|
160,914,935
|
|
Accounts
receivable
|
4,770,773
|
|
|
18,559,967
|
|
Accounts receivable
from affiliated entities
|
2,354,316
|
|
|
503,782
|
|
Prepaid expenses and
other current assets
|
85,331,311
|
|
|
40,357,456
|
|
Prepaid expenses and
other current assets from affiliated entities
|
—
|
|
|
106,432
|
|
Total current
assets
|
487,396,973
|
|
|
471,170,690
|
|
Fixed assets,
net
|
17,579,013
|
|
|
11,348,144
|
|
Investment in
affiliated entity
|
3,886,710
|
|
|
4,460,366
|
|
Investment in
Geneos
|
—
|
|
|
434,387
|
|
Intangible assets,
net
|
2,753,126
|
|
|
3,146,770
|
|
Goodwill
|
10,513,371
|
|
|
10,513,371
|
|
Operating lease
right-of-use assets
|
11,878,236
|
|
|
12,741,296
|
|
Other
assets
|
1,755,083
|
|
|
25,957,448
|
|
Total
assets
|
$
|
535,762,512
|
|
|
$
|
539,772,472
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
Current
liabilities:
|
|
|
Accounts payable and
accrued expenses
|
$
|
28,654,864
|
|
|
$
|
21,203,808
|
|
Accounts payable and
accrued expenses due to affiliated entities
|
491,645
|
|
|
642,969
|
|
Accrued clinical
trial expenses
|
13,618,825
|
|
|
9,950,345
|
|
Deferred
revenue
|
77,878
|
|
|
46,628
|
|
Operating lease
liability
|
2,536,399
|
|
|
2,329,394
|
|
Grant funding
liability
|
5,964,931
|
|
|
7,474,310
|
|
Grant funding
liability from affiliated entity
|
31,250
|
|
|
58,500
|
|
Total current
liabilities
|
51,375,792
|
|
|
41,705,954
|
|
Deferred revenue, net
of current portion
|
68,075
|
|
|
79,214
|
|
Convertible senior
notes
|
14,479,334
|
|
|
14,139,988
|
|
Convertible
bonds
|
—
|
|
|
4,515,834
|
|
Operating lease
liability, net of current portion
|
16,133,245
|
|
|
18,063,515
|
|
Deferred tax
liabilities
|
32,046
|
|
|
32,046
|
|
Grant funding
liability from affiliated entity, net of current portion
|
37,500
|
|
|
37,500
|
|
Other
liabilities
|
64,141
|
|
|
57,663
|
|
Total
liabilities
|
82,190,133
|
|
|
78,631,714
|
|
Stockholders'
equity:
|
|
|
Preferred
stock
|
—
|
|
|
—
|
|
Common
stock
|
210,362
|
|
|
186,851
|
|
Additional paid-in
capital
|
1,556,527,891
|
|
|
1,367,406,869
|
|
Accumulated
deficit
|
(1,102,907,942)
|
|
|
(906,196,812)
|
|
Accumulated other
comprehensive loss
|
(257,932)
|
|
|
(256,150)
|
|
Total Inovio
Pharmaceuticals, Inc. stockholders' equity
|
453,572,379
|
|
|
461,140,758
|
|
Total liabilities
and stockholders' equity
|
$
|
535,762,512
|
|
|
$
|
539,772,472
|
|
INOVIO
Pharmaceuticals, Inc. CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS
(Unaudited)
|
|
|
Three Months
Ended
September 30,
|
Nine Months
Ended
September 30,
|
|
|
2021
|
|
2020
|
|
2021
|
|
2020
|
|
Revenues:
|
|
|
|
|
|
Revenue under
collaborative research and development arrangements
|
$
|
81,447
|
|
|
$
|
21,490
|
|
|
$
|
203,985
|
|
|
$
|
167,092
|
|
Revenue under
collaborative research and development arrangements with affiliated
entities
|
95,136
|
|
|
103,684
|
|
|
219,872
|
|
|
1,370,956
|
|
Other
revenue
|
115,115
|
|
|
111,004
|
|
|
511,786
|
|
|
292,591
|
|
Total
revenues
|
291,698
|
|
|
236,178
|
|
|
935,643
|
|
|
1,830,639
|
|
Operating
expenses:
|
|
|
|
|
|
Research and
development
|
47,088,669
|
|
|
26,455,112
|
|
|
156,941,505
|
|
|
67,942,875
|
|
General and
administrative
|
13,156,183
|
|
|
10,110,506
|
|
|
39,703,718
|
|
|
28,630,370
|
|
Total operating
expenses
|
60,244,852
|
|
|
36,565,618
|
|
|
196,645,223
|
|
|
96,573,245
|
|
Loss from
operations
|
(59,953,154)
|
|
|
(36,329,440)
|
|
|
(195,709,580)
|
|
|
(94,742,606)
|
|
Other income
(expense):
|
|
|
|
|
|
Interest
income
|
766,271
|
|
|
896,710
|
|
|
2,463,618
|
|
|
2,380,678
|
|
Interest
expense
|
(476,374)
|
|
|
(1,984,046)
|
|
|
(1,456,134)
|
|
|
(7,634,442)
|
|
Change in fair value
of derivative liability
|
—
|
|
|
35,306,000
|
|
|
—
|
|
|
(75,670,977)
|
|
Gain (loss) on
investment in affiliated entities
|
(21,999)
|
|
|
26,951,898
|
|
|
(573,656)
|
|
|
36,250,341
|
|
Net unrealized gain
(loss) on available-for-sale equity securities
|
(455,299)
|
|
|
1,315,980
|
|
|
(1,166,764)
|
|
|
624,522
|
|
Other income
(expense), net
|
(28,486)
|
|
|
(136,644)
|
|
|
165,773
|
|
|
(714,246)
|
|
Gain on
deconsolidation of Geneos
|
—
|
|
|
—
|
|
|
—
|
|
|
4,121,075
|
|
Loss on
extinguishment of convertible bonds
|
—
|
|
|
(8,177,043)
|
|
|
—
|
|
(8,177,043)
|
|
Gain on
extinguishment of convertible senior notes
|
—
|
|
|
3,087,595
|
|
|
—
|
|
3,087,595
|
|
Net income (loss)
before income tax benefit and share in net loss of
Geneos
|
(60,169,041)
|
|
|
20,931,010
|
|
|
(196,276,743)
|
|
|
(140,475,103)
|
|
Share in net loss of
Geneos
|
—
|
|
|
(1,759,674)
|
|
|
(434,387)
|
|
|
(2,661,431)
|
|
Net income
(loss)
|
(60,169,041)
|
|
|
19,171,336
|
|
|
(196,711,130)
|
|
|
(143,136,534)
|
|
Net loss attributable
to non-controlling interest
|
—
|
|
|
—
|
|
|
—
|
|
|
1,063,757
|
|
Net income (loss)
attributable to Inovio Pharmaceuticals, Inc.
|
(60,169,041)
|
|
|
19,171,336
|
|
|
(196,711,130)
|
|
|
(142,072,777)
|
|
Net income (loss)
per share attributable to Inovio Pharmaceuticals, Inc.
stockholders
|
|
|
|
|
|
Basic
|
(0.29)
|
|
|
0.12
|
|
|
(0.95)
|
|
|
(0.96)
|
|
Diluted
|
(0.29)
|
|
|
0.11
|
|
|
(0.95)
|
|
|
(0.96)
|
|
Weighted average
number of common shares outstanding
|
|
|
|
|
|
Basic
|
210,304,836
|
|
|
165,355,540
|
|
|
207,455,684
|
|
|
148,656,454
|
|
Diluted
|
210,304,836
|
|
|
174,376,402
|
|
|
207,455,684
|
|
|
148,656,454
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
View original
content:https://www.prnewswire.com/news-releases/inovio-reports-third-quarter-2021-financial-results-301420363.html
SOURCE INOVIO Pharmaceuticals, Inc.